US20230248704A1 - Il-8 inhibitors for use in the treatment of some sarcomas - Google Patents
Il-8 inhibitors for use in the treatment of some sarcomas Download PDFInfo
- Publication number
- US20230248704A1 US20230248704A1 US18/135,460 US202318135460A US2023248704A1 US 20230248704 A1 US20230248704 A1 US 20230248704A1 US 202318135460 A US202318135460 A US 202318135460A US 2023248704 A1 US2023248704 A1 US 2023248704A1
- Authority
- US
- United States
- Prior art keywords
- inhibitor
- alkyl
- linear
- branched
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 67
- 206010039491 Sarcoma Diseases 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title abstract description 48
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 80
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 80
- 210000004072 lung Anatomy 0.000 claims abstract description 55
- 201000008968 osteosarcoma Diseases 0.000 claims abstract description 55
- 206010027476 Metastases Diseases 0.000 claims abstract description 40
- 230000009401 metastasis Effects 0.000 claims abstract description 37
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims abstract description 37
- 208000006168 Ewing Sarcoma Diseases 0.000 claims abstract description 30
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims abstract description 16
- 108010018976 Interleukin-8A Receptors Proteins 0.000 claims abstract description 13
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims abstract description 13
- 102000002791 Interleukin-8B Receptors Human genes 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 206010006007 bone sarcoma Diseases 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- -1 1,3-thiazol-2-ylaminophenylpropionic acid derivative compound Chemical class 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 4
- OUGCUPYREMACGK-ZETCQYMHSA-N (2s)-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical group C1=CC([C@@H](C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 OUGCUPYREMACGK-ZETCQYMHSA-N 0.000 claims description 3
- RBHRISLTYCPPMU-UHFFFAOYSA-N 2-phenyl-2-(1,3-thiazol-2-ylamino)propanoic acid Chemical group C=1C=CC=CC=1C(C)(C(O)=O)NC1=NC=CS1 RBHRISLTYCPPMU-UHFFFAOYSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- TVKXUJXIOMUVFS-UHFFFAOYSA-N 2-methyl-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 TVKXUJXIOMUVFS-UHFFFAOYSA-N 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 206010027458 Metastases to lung Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 38
- 230000002265 prevention Effects 0.000 abstract description 30
- 230000009977 dual effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 30
- 102000004889 Interleukin-6 Human genes 0.000 description 29
- 108090001005 Interleukin-6 Proteins 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 24
- 229940100601 interleukin-6 Drugs 0.000 description 24
- DDLPYOCJHQSVSZ-SSDOTTSWSA-N [4-[(2r)-1-(methanesulfonamido)-1-oxopropan-2-yl]phenyl] trifluoromethanesulfonate Chemical compound CS(=O)(=O)NC(=O)[C@H](C)C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 DDLPYOCJHQSVSZ-SSDOTTSWSA-N 0.000 description 20
- 206010061289 metastatic neoplasm Diseases 0.000 description 20
- 230000001394 metastastic effect Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000035605 chemotaxis Effects 0.000 description 5
- 230000007646 directional migration Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003622 mature neutrocyte Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- PHQYATBUISXTPG-NZPFSMCRSA-N (4R)-3-[(2S,3S)-3-hydroxy-2-methyl-4-methylidenenonanoyl]-4-propan-2-yloxolan-2-one Chemical compound O[C@@H]([C@@H](C(=O)C1C(OC[C@@H]1C(C)C)=O)C)C(CCCCC)=C PHQYATBUISXTPG-NZPFSMCRSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940125528 allosteric inhibitor Drugs 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000010002 chemokinesis Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- UDXWSYOXIRPYFK-RRFJBIMHSA-N (4s)-3-[(2s,3s)-3-hydroxy-2-methyl-4-methylidenenonanoyl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CCCCCC(=C)[C@@H](O)[C@H](C)C(=O)N1[C@@H](C(C)C)COC1=O UDXWSYOXIRPYFK-RRFJBIMHSA-N 0.000 description 1
- NRJUWEPWHLIMBQ-UHFFFAOYSA-N 2-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)-1H-pyrazine-2-carbohydrazide Chemical compound FC=1C=C2N=C(C=3N(C2=CC=1)C=CC=3)C1(NC=CN=C1)C(=O)NN NRJUWEPWHLIMBQ-UHFFFAOYSA-N 0.000 description 1
- OUGCUPYREMACGK-UHFFFAOYSA-N 2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 OUGCUPYREMACGK-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229940126750 DF2755A Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101000916059 Homo sapiens C-X-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 238000007807 Matrigel invasion assay Methods 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229950001565 clazakizumab Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000012142 en-bloc resection Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 102000055357 human CXCR2 Human genes 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229950010517 ladarixin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000011395 multi-agent chemotherapy Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 229950010006 olokizumab Drugs 0.000 description 1
- 108091008820 oncogenic transcription factors Proteins 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 201000010791 peripheral nerve sheath neoplasm Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000010825 regulation of cytoskeleton organization Effects 0.000 description 1
- 229950005650 reparixin Drugs 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229950007269 vobarilizumab Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to IL-8 inhibitors for the prevention and/or treatment of some sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
- the invention also relates to a pharmaceutical composition, product/kit comprising an IL-8 inhibitor with an IL-6 inhibitor or with a chemotherapeutic agent.
- Bone and soft tissue sarcomas are a group of rare heterogeneous forms of cancer, which collectively account for approximately 1% of all malignancies diagnosed. Sarcomas represent a challenge to clinicians as they are rare and diagnosis is often delayed.
- Soft tissue sarcomas develop from soft tissue cells including smooth muscle cells (leiomyosarcomas), fat cells (liposarcomas), fibrous connective tissue (fibrosarcomas), skeletal muscles (rhabdomyosarcomas), synovium (synovial sarcomas), blood vessels (angiosarcomas), breast ducts (phyllodes tumours) and nerves (nerve sheath tumours).
- Osteosarcoma is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and that exhibits osteoblastic differentiation and produces malignant osteoid.
- a complete radical, surgical, en bloc resection of the cancer is the treatment of choice in osteosarcoma. Although about 90% of patients are able to have limb-salvage surgery, complications, particularly infection, prosthetic loosening and non-union, or local tumor recurrence may cause the need for further surgery or amputation.
- Standard therapy is a combination of limb-salvage orthopedic surgery when possible (or amputation in some cases) and chemotherapy.
- Ewing sarcoma is a highly aggressive bone tumor with peak incidence in the adolescent population. It has a high propensity to metastasize, which is associated with dismal survival rates of approximately 25% (Satterfield, L. et al, Int. J. Cancer, 141: 2062-2075; 2017; Beverly A. Teicher et al, Ann Saudi Med., 31(2): 174-182; 2011).
- EWS/FLl1 plays a dominant role in tumor progression by modulating the expression of hundreds of target genes.
- EWS/FLl1 inhibition by RNAi-mediated knockdown, on cellular signaling was investigated using mass spectrometry-based phosphoproteomics to quantify global changes in phosphorylation.
- This unbiased approach identified hundreds of unique phosphopeptides enriched in processes such as regulation of cell cycle and cytoskeleton organization.
- phosphotyrosine profiling revealed a large upregulation of STAT3 phosphorylation upon EWS/FLl1 knockdown.
- Rhabdomyosarcoma is an aggressive and highly malignant form of cancer that develops from skeletal (striated) muscle cells that have failed to fully differentiate. It is generally considered to be a disease of childhood, as the vast majority of cases occur in those below the age of 18.
- RMS soft-tissue sarcoma
- rhabdomyosarcoma Treatment of rhabdomyosarcoma is a multidisciplinary practice involving the use of surgery, chemotherapy, radiation, and possibly immunotherapy. Surgery is generally the first step in a combined therapeutic approach. Resectability varies depending on tumor site, and RMS often presents in sites that don’t allow for full surgical resection without significant morbidity and loss of function. Less than 20% of RMS tumors are fully resected with negative margins. Fortunately, rhabdomyosarcomas are generally chemosensitive, with approximately 80% of cases responding to chemotherapy.
- Multi-agent chemotherapy is indicated for all patients with rhabdomyosarcoma.
- treatment solely by surgical means had a survival rate of ⁇ 20%.
- Modern survival rates with adjuvant therapy are approximately 60-70%.
- Metastasis kills patients with solid tumors. Nowhere is this more evident than in osteosarcoma.
- the deadly bone cancer osteosarcoma (OS) kills primarily through metastatic spread to lung.
- the mechanisms driving this lung tropism remain unknown. Whether patients present with grossly metastatic disease at diagnosis or metastases arise many years after completing therapy, patients with localized disease enjoy a relatively favorable 70% 5-year overall survival rate, while those with lung metastasis suffer an abysmal 15% 2-year survival (Allison D. C. et al; Sarcoma 2012, 704872; 2012).
- a therapy which prevents the emergence of lung metastasis in children and adolescents with osteosarcoma would save the lives of more than 70% of those who currently die from their disease.
- Interleukin-8 (IL-8; CXCL8) is considered a major mediator of PMN (Polymorphonuclear Neutrophils) recruitment and is involved in several pathologies including psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease and reperfusion injury in transplanted organ (Griffin et al, Arch Dermatol 1988, 124: 216; Fincham et al, J Immunol 1988, 140: 4294; Takematsu et al, Arch Dermatol 1993, 129: 74; Liu et al, 1997, 100:1256; Jeffery, Thorax 1998, 53: 129; Pesci et al, Eur Respir J.
- PMN Polymorphonuclear Neutrophils
- IL-8 The biological activity of IL-8 is mediated by the interaction with two receptors, CXCR1 and CXCR2, belonging to the 7 TM-GPCR family, that are expressed on the surface of human PMNs.
- CXCR1 is selective, binding with high affinity only two chemokines, CXCL6 and IL-8, and showing a much higher affinity for IL-8 (Wolf et al, Eur J Immunol 1998, 28: 164)
- human CXCR2 is a more promiscuous receptor, binding a number of different cytokines and chemokines. Therefore, CXCR2 mediates the activity of a number of different biological molecules.
- Interleukin-6 (IL-6) is a pleiotropic cytokine with multiple functions in immune regulation, inflammation, and oncogenesis. Binding of IL-6 to the IL-6 receptor (IL-6R) induces homodimerization and recruitment of glycoprotein 130 (gp130), which leads to activation of downstream signaling.
- Gp130 is part of the receptor signaling complexes for at least 8 cytokines (IL-6, IL-11, IL-27, LIF, CNTF, OSM, CT-1, and CLC). Ligand binding induces the association of gp130 with a cytokine-specific receptor-a chain, followed by the activation of downstream signaling cascades including JAK/STAT, RAS/RAF/MAPK, and Pl3K/AKT pathways. It has been shown that phosphorylation of gp130 at Ser782 downregulates cell surface expression of gp130. As a ubiquitously expressed receptor, gp130 is involved in a wide range of important biologic processes including inflammation, autoimmunity, cancer, stemcell maintenance, and embryonic development (Mol Cancer Ther; 12(6); 937-49; 2013).
- cytokines IL-6, IL-11, IL-27, LIF, CNTF, OSM, CT-1, and CLC.
- the present inventors have surprisingly found that inhibition of IL-8 is able to reduce or prevent the occurrence of lung metastasis associated with osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- the combination of an IL-8 inhibitor with an IL-6 inhibitor is resulted more effective.
- an IL-8 inhibitor is useful in the prevention and/or treatment of the primary tumor osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- IL-8 inhibitor is combined with a chemotherapeutic agent.
- a first object of the present invention is an IL-8 inhibitor, preferably an antibody or a small molecular weight molecule, preferably a CXCR1 inhibitor, more preferably a dual CXCR1 /CXCR2 inhibitor, for use in the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
- the second object of the present invention is the use of said IL-8 inhibitor as defined above, for the preparation of a medicament for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
- the third object of the present invention is a method for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof comprising the step of administering to a subject in need thereof a therapeutically effective amount of said IL-8 inhibitor.
- the fourth object of the invention is a pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof comprising an IL-8 inhibitor according to the invention and pharmaceutically acceptable excipients and/or diluents.
- said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably lung metastasis, further comprises at least one IL-6 inhibitor and/or at least one gp130 inhibitor.
- said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably the primary tumor, further comprises at least one chemotherapeutic agent.
- the fifth and sixth object of the present invention are a product or a kit for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, comprising an IL-8 inhibitor as defined above and one or more pharmaceutically active compounds for simultaneous, separate or sequential use.
- FIG. 1 shows IL6 and IL8 expression correlate with metastatic efficiency and metastatic behaviors in xenograft models of metastasis.
- CB17-SCID mice inoculated with 1 ⁇ 10 6 OS cells were euthanized 49 days after innoculation.
- H&E stains from sections of paraffin-embedded left lobes were counted to quantify the number of metastases per section.
- Quantification reveals significantly higher numbers of metastases in the OS-17 sections relative to OHS.
- FIG. 2 shows effect of DF2156A alone or in combination with sc144 to reduce chemotactic responses to serum in OS-17 cells.
- OS cells were cultured on a transwell chamber membrane, then subjected transferred to a chamber containing RPMI with 2.5% FBS (pos ctl) or RPMI alone (neg ctl).
- Other wells containing 2.5% FBS in the bottom chamber were treated with 1 uM sc144, 10 nM DF2156A, or both. After 24 hours, top chambers were scraped clean, membranes stained and cells counted.
- FIG. 3 shows effects of IL-6 and IL-8 pathway inhibition on metastatic lung colonization.
- Mice innoculated with 1 ⁇ 10 6 OS-17-luc cells were treated with pharmacologic inhibitors of IL-6 (sc144), IL-8 (DF2156A), or both.
- FIG. 4 shows PD analysis in lung tissue of mice treated with DF2156A and sc144.
- Mice treated with injections of either DF2156A or sc144 daily were euthanized 24 hours subsequent to their 14 th dose of drug.
- Lungs harvested from those mice were processed using standard FFPE, then sectioned and stained with IHC for either pFAK (downstream of IL-8) or pSTAT3 (downstream of IL-6).
- Receptor blockade reduced the amount of activation seen and the number of infiltrating cells, even at trough concentrations.
- FIG. 5 shows effect of the combination DF2156A with sc144 in the prevention of lung metastasis in multiple models of OS. Subsequent to inoculation of OS cells, mice received either vehicle treatment or treatment with both sc144 and DF2156A for a period of 42 days. At the time that one mouse in either group met endpoint criteria, all mice within that study were euthanized and lungs harvested, metastatic lesions counted.
- the present inventors have found that molecules acting as inhibitors of IL-8 activity have therapeutic efficacy in animal models of sarcoma. Furthermore, the present inventors have also found that IL-8 inhibition is able to counteract the onset of lung metastasis. In particular, the combined IL-8 and IL-6 inhibition prevents metastasis.
- a first object of the present invention is an IL-8 inhibitor for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- said IL-8 inhibitor is for use in the prevention and/or treatment of lung metastasis associated to osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- L-8-inhibitor refers to any compound able to inhibit, partially or totally, the biological activity of IL-8. Such a compound can act by decreasing the expression or activity of IL-8 or by inhibiting the triggering of the intracellular signaling activated by the IL-8 receptors. It is preferred that said IL-8 inhibitor is able to inhibit at least 50%, preferably at least 60%, of the chemotaxis induced by IL-8 in PMNs at a concentration equal or below 500 nM, preferably below 100 nM.
- the IL-8 inhibitor of all the objects of the present invention inhibits the activity of IL-8 mediated by CXCR1 receptor or mediated by both CXCR1 and CXCR2 receptors.
- said IL-8 inhibitor is either an allosteric inhibitor or an orthosteric antagonist of CXCR1 receptor or of both CXCR1 and CXCR2 receptors.
- said IL-8 inhibitor is selective for CXCR1 receptor or is equally potent towards CXCR1 and CXCR2 receptors.
- selective for CXCR1 it is meant a compound that shows an IC 50 value at least 2, preferably 3, logs higher toward CXCR1 than towards CXCR2. (Bertini R. et al., Proc. Nat. Acad. Sci. USA (2004), 101 (32), pp. 11791-11796).
- the IL-8 inhibitor according to the invention has an IC 50 value towards CXCR1 receptor in the low nanomolar range, preferably in the range 0.02-5 nanomolar.
- said IL-8 inhibitor is selected from small molecular weight molecules and antibodies, more preferably it is a small molecular weight molecule.
- IL-8 inhibitors according to the above definition, able to inhibit the activity of IL-8 mediated by CXCR1 receptor or mediated by both CXCR1 and CXCR2 receptors, are known in the art.
- Preferred IL-8 inhibitors according to the invention are selected from 1,3-thiazol-2-ylaminophenylpropionic acid derivatives, 2-phenyl-propionic acid derivatives and their pharmaceutically acceptable salts.
- said 1,3-thiazol-2-ylaminophenylpropionic acid derivative is preferably a compound of formula (l):
- these compounds X is OH.
- the chiral carbon atom of the phenylpropionic group is in the S configuration.
- WO2010/031835 discloses their method of synthesis, their activity as IL-8 inhibitors as well as their use in the treatment of IL-8 dependent pathologies such as transient cerebral ischemia, bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion.
- said 2-phenyl-propionic acid derivative is preferably a compound of formula (II):
- R 4 is linear or branched C 1 -C 6 alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy; preferably it is selected from benzoyl, isobutyl and trifluoromethanesulfonyloxy. Also, according to a preferred embodiment R 4 is in position 3 or 4 on the phenyl ring, more preferably it is 3-benzoyl, 4-isobutyl or 4- trifluoromethanesulfonyloxy.
- R 5 is H or linear or branched C 1 -C 3 alkyl, preferably it is H.
- R 6 is linear or branched C 1 -C 6 alkyl or trifluoromethyl; preferably, it is a linear or branched C 1 -C 6 alkyl, more preferably it is CH 3 .
- the chiral carbon atom of the phenylpropionic group is in the R configuration.
- Particularly preferred compounds of formula (II) according to the invention are selected from R-(-)-2-(4-isobutylphenyl)propionyl methansulfonamide (also known as Reparixin) and pharmaceutically acceptable salts thereof.
- said compound is the lysine in situ salt of R(-)-2-(4-isobutylphenyl)propionyl methansulfonamide (herein indicated also as DF1681B).
- compounds of formula (II) or (III) according to the invention are 2-(4-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide and pharmaceutically salts thereof, preferably its sodium salt preferably R(-)-2-(4-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide (also known as DF2156Y) and its sodium salt (also known as Ladarixin or DF2156A).
- IL-8 inhibitors of formula (II) and (III) are disclosed in WO0024710 and WO2005/090295, that also disclose their method of synthesis, their activity as IL-8 inhibitors as well as their use as inhibitors of neutrophils chemotaxis and degranulation induced by IL-8 and in the treatment of IL-8 dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary diseases (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion.
- COPD chronic obstructive pulmonary diseases
- the second object of the present invention is the use of an IL-8 inhibitor for the preparation of a medicament for the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- said medicament is for the treatment and/or prevention of lung metastasis associated to bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- the third object of the present invention is a method for the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma, comprising the step of administering to the subject in need thereof, a therapeutically effective amount of an IL-8 inhibitor, as defined above.
- said method is for the treatment and/or prevention of lung metastasis associated to bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- a “therapeutically effective amount” refers to an amount sufficient to achieve treatment or prevention of the disease. Determination of the effective amounts is well within the capability of those skilled in the art based upon the achievement of a desired effect. An effective amount will depend on factors including, but not limited to, the weight of a subject and/or the degree of the disease or unwanted condition from which a subject suffers.
- treatment refers to the eradication/amelioration or prevention/delay in onset, respectively, of the disorder being treated or of one or more of the symptoms associated thereof, notwithstanding the fact that the patient may still be afflicted with the underlying disorder.
- the fourth object of the present invention is a pharmaceutical composition comprising an IL-8 inhibitor as defined above, for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof in association with pharmaceutically acceptable excipients and/or diluents.
- an IL-8 inhibitor as defined above, for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof in association with pharmaceutically acceptable excipients and/or diluents.
- said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably lung metastasis, further comprises at least one IL-6 inhibitor and/or at least one gp130 inhibitor.
- IL-6 inhibitor refers to any compound able to inhibit, partially or totally, the biological activity of IL-6.
- gp130 inhibitor refers to any compound able to inhibit, partially or totally, the biological activity of gp130.
- said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably the primary tumor further comprises at least one chemotherapeutic agent.
- the fifth object of the present invention is a product or kit comprising: A) an IL-8 inhibitor as defined above for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof or a pharmaceutical composition as defined above, and B) at least one IL-6 inhibitor and/or at least one gp130 inhibitor, A) and B) being two separate formulations for simultaneous, separate or sequential use.
- an IL-8 inhibitor as defined above for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof or a pharmaceutical composition as defined above
- B) at least one IL-6 inhibitor and/or at least one gp130 inhibitor being two separate formulations for simultaneous, separate or sequential use.
- lung metastasis associated to osteosarcoma Ewing
- said gp130 inhibitor is selected from the group comprising 2-(7-Fluoropyrrolo[1,2-a]quinoxalin-4-yl) 2-pyrazinecarboxylic acid hydrazide (SC144), Raloxifene and (4R)-3-((2 S,3 S)-3-hydroxy-2-methyl-4-methylenenonanoyl)-4-isopropyldihydrofuran-2(3H)-one (LMT-28) (Tae-Hwe Heo et al.; Oncotarget, Vol. 7, No. 13, 15460- 15473; 2016).
- said IL-6 inhibitor is selected from the group comprising SC144, Vobarilizumab, Siltuximab, Sirukumab, Olokizumab, Clazakizumab, MAb 1339, Tocilizumab and Sarilumab (Tae-Hwe Heo et al.; Oncotarget, Vol. 7, No. 13, 15460- 15473; 2016).
- said IL-6 inhibitor is SC144.
- the sixth object of the present invention is a product or kit comprising: A′) an IL-8 inhibitor as defined above for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof or a pharmaceutical composition as defined above, and B′) at least one chemotherapeutic agent, A′) and B′) being two separate formulations for simultaneous, separate or sequential use.
- the primary tumor osteosarcoma Ewing sarcoma or rhabdomyosarcoma.
- said chemotherapeutic agent is selected from the group comprising doxorubicin, cisplatin, methotrexate, ifosfamide, epirubicin, etoposide, cyclophosphamide, vincristine and actinomycin D.
- the inhibitors of IL-8 according to the present invention are formulated in pharmaceutical compositions suitable for use by oral formulation, such as tablets, capsules, syrups, preferably in the form of controlled release formulations, or by parenteral administration, preferably in the form of sterile solutions suitable for intravenous or intramuscular administration.
- oral formulation such as tablets, capsules, syrups
- parenteral administration preferably in the form of sterile solutions suitable for intravenous or intramuscular administration.
- the pharmaceutical compositions can be prepared according to conventional methods, for example as disclosed in Remington, “The Science and Practice of Pharmacy”, 21st ed. (Lippincott Williams and Wilkins).
- the average daily dose depends on several factors such as the severity of the disease, the condition, age, sex and weight of the patient.
- the dose will vary generally from 1 to 1500 mg of compounds of formula (l) per day optionally divided in multiple administrations.
- OS-17 was derived from the OS-17 xenograft and obtained from the Istituti Ortopedici Rizzoli, Bologna, Italy.
- OS-25 and OHS were a gift from Dr. Fodstad’s lab at the Radium Hospital in Oslo. All were maintained in RPMI (Corning #10-040-CV) supplemented with 10% FBS (Atlanta Biologicals #S11150H).
- FBS Antlanta Biologicals #S11150H
- 143B and K7M2 cells were obtained from ATCC (ATCC #CRL ⁇ 8303 and #CRL2836) and grown in DMEM (Corning #10-013-CV) supplemented with 10% FBS.
- OSCA-8 and OSCA-16 were provided by Jamie Modiano and the University of Minnesota and grown in RPMI with 10% FBS.
- Lung smooth muscle cells (ATCC #PCS-130-10) were grown in vascular cell basal medium (ATCC #PCS-100-030) supplemented with the vascular smooth muscle cell growth kit (ATCC #PCS-100-042).
- HUVEC cells (Lonza CC-2517) were grown in endothelial basal medium (Lonza #CC-5036) supplemented with the EGM-plus single quote (Lonza #CC-4542).
- Human lung fibroblasts (ATCC #PCS-201-013) were grown in EMEM (ATCC #30-2003) supplemented with 10% FBS.
- HBEC3-KT cells (ATCC #CRL-4051) were grown in airway epithelial cell basal medium (ATCC #PCS-300-030) supplemented with the bronchial epithelial cell growth kit (ATCC #PCS-300-040).
- Macrophages were derived from monocytes isolated from whole blood (obtained through an institutional IRB-approved protocol for the procurement of fresh human blood) using a CD14 magnetic bead selection system (Miltenyi #130-050-201) followed by 72 hours of culture in XVIVO serum-free medium (Lonza #04-380Q) supplemented daily with 20 ng/ml of recombinant human M-CSF (BioLegend #574802).
- cultures within each group co-culture and related monocultures were performed using a 1:1 mixture of the two corresponding growth media to control for differences in media components.
- IL-6 and IL-8 ELISA Cell-free supernatants from 72-hour cultures of each cell line performed in 24-well plates were evaluated for IL-6 and IL-8 concentrations using R&D DuoSet ELISA Development Kits (#DY206 and #DY208), used according to manufacturer recommendations.
- Transwell migration and invasion assays 1 ⁇ 10 4 OS cells were plated into transwell inserts (either Falcon #353097 for migration or Corning #354483 for Matrigel invasion assays) containing appropriate chemotactic factors. After 24 hours of incubation, transwells were drained and upper chambers/membrane upper surfaces scraped using a polyester swab. Membranes were stained using a Dif-Quik Stain Set (Siemens #B4132-1A) and dried, then imaged on an inverted microscope. Cells were quantified using Adobe Photoshop counting tools.
- media contained 1% FBS in both chambers, with recombinant protein added to the bottom chamber to make 50 ng/ml IL6 (BioLegend #570804) or 100 ng/ml IL-8 (BioLegend #574204).
- top chambers contained RPMI only, while bottom chambers contained 1% or 2.5% serum.
- 20 ug/ml of neutralizing antibodies to either IL6 (Abcam #AB6672), IL-8 (Abcam #AB18672), or both were added to both upper and lower chambers.
- OS cell proliferation Cells plated at 20% confluence were cultured in growth medium as above containing inhibitors as noted in each figure. Proliferation was serially quantified using an Essen Biosciences Incucyte Zoom over the time period noted in each figure.
- CB17-SCID mice inoculated via tail vein with 1 ⁇ 10 6 OS-17 cells (day 0) received daily injections of sc144 (10 mg/kg SC once daily, Sigma #SML0763), DF2156A (30 mg/kg IP once daily), or both beginning 24 hours after inoculation.
- sc144 was prepared by dissolving with warming in DMSO to make a 40 mg/kg solution, which was immediately diluted to 2 mg/kg using 40% propylene glycol/1% Tween-20 in water. An average 20 g mouse received 100 ul per dose. Doses of sc144 were prepared fresh each day.
- DF2156A was prepared by dissolving in PBS to create a 6 mg/ml solution for similar 100 ul doses in a 20 g mouse. Treatments continued for 42 days, then stopped. Mice were monitored with twice weekly weights and enhanced body condition scoring (eBCS (28)). Mice demonstrating >10% weight loss or eBCS ⁇ 8 were euthanized and tissues harvested, lungs insufflated, fixed in 10% neutral buffered formalin, then embedded and processed as above. Mice not demonstrating metastatic disease burden (presumably dying from other causes) are censored in the survival analysis. This includes 2 mice receiving combined therapy, one receiving sc144, and one control mouse.
- eBCS enhanced body condition scoring
- mice 6-8 week old CB17-SCID mice were inoculated with 1 ⁇ 10 6 143B, OSCA-8, OSCA-16, or K7M2 cells (for K7M2 cells, immunocompetent Balb/c mice were used). 24 hours after inoculation, mice began treatment with daily sc144 and/or DF2156A, which continued for 42 days as above. Mice were then observed as above until one mouse from any given cell line group reached endpoint. If lungs taken from this sentinel mouse showed signs of metastatic disease, all mice from that group were euthanized, lungs harvested, insufflated, fixed, embedded, and stained. A central section of the left lobe stained with H&E was reviewed using microscopy to count metastatic lesions by an experienced, blinded reviewer.
- the present inventors tested a panel of osteosarcoma cell lines for their ability to colonize mouse lung.
- the present inventors found that OS-17 cells, when introduced into circulation via tail vein, develop metastatic loci with very high efficiency, while OHS cell lines demonstrate much lower metastatic efficiency ( FIG. 1 ). This effect remained consistent across multiple passages of cells and multiple assays.
- the present inventors tested these cell lines for production of IL-6 and IL-8 by subjecting cell-free supernatants to ELISA ( FIG. 1 d ), which revealed a strong correlation between tumor cell production of both of these cytokines and the cell line’s capacity to colonize murine lung.
- IL-6 and IL-8 Stimulate Chemokinesis and Directional Migration in OS Cells, Regardless of Metastatic Potential
- IL-6 and/or IL-8 blockade might have when using serum as a chemoattractant. Both cell lines demonstrated very strong both transwell migration and invasion through a matrigel barrier in response to a chemotactic gradient of serum ( FIGS. 1 e - f ). Some decrease in the chemotactic response was evident when IL-6 or IL-8 blocking antibodies were added to the culture medium, though a much more profound effect was seen when the antibodies were combined.
- mice inoculated via tail vein with 1 ⁇ 10 6 luciferase-labeled OS-17 cells received treatment with sc144 (the gp130 inhibitor), DF2156A (the CXCR1 ⁇ 2 inhibitor), or both. Mice continued to receive treatment for 42 days, after which treatment stopped.
- Intravital imaging for in vivo assessment of tumor burden was performed at 14 and 24 days using standard bioluminescent techniques. Bioluminescent imaging suggested markedly decreased tumor burden in the lungs of mice receiving combined therapy relative to those receiving no treatment or single-agent therapy ( FIG. 3 A ).
- mice from each single-agent treatment group were euthanized 24 hours after the 14 th dose of drug to perform pharmacodynamics (PD) assessment of target inhibition.
- Lungs from those mice stained with IHC for either pFAK (DF2156A) or pSTAT3 (gp130) showed sustained target inhibition (i.e. sustained drug activity) at dosing trough ( FIG. 4 ).
- mice Following treatment, mice were then observed until demonstrating signs of clinical deterioration, either weight loss >10% or enhanced body condition score (eBCS) ⁇ 8, our defined endpoints.
- eBCS enhanced body condition score
- mice were euthanized using approved methods and lungs were harvested, insufflated, fixed, embedded, sectioned, and stained.
- the present inventors repeated the treatment-related experiments using a number of different models. These included a syngeneic, immunocompetent model using a cell line derived from a spontaneously-arising OS in a Balb/c mouse (K7M2), xenograft models of canine OS (OSCA-8 and OSCA-16), and additional xenograft models of human OS (143B). Mice inoculated with tumor cells were treated with either no drug or combined sc144 and DF2156A for 42 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The present invention relates to IL-8 inhibitors for the prevention and/or treatment of some sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof. The invention also relates to a pharmaceutical composition, product/kit comprising an IL-8 inhibitor with an IL-6 inhibitor or with a chemotherapeutic agent.
- Bone and soft tissue sarcomas are a group of rare heterogeneous forms of cancer, which collectively account for approximately 1% of all malignancies diagnosed. Sarcomas represent a challenge to clinicians as they are rare and diagnosis is often delayed.
- There are over one hundred different morphological sub-types of sarcoma. The most common types of bone sarcoma are osteosarcoma, chondrosarcoma, Ewing sarcoma and chordoma. Soft tissue sarcomas develop from soft tissue cells including smooth muscle cells (leiomyosarcomas), fat cells (liposarcomas), fibrous connective tissue (fibrosarcomas), skeletal muscles (rhabdomyosarcomas), synovium (synovial sarcomas), blood vessels (angiosarcomas), breast ducts (phyllodes tumours) and nerves (nerve sheath tumours).
- Osteosarcoma (OS) is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and that exhibits osteoblastic differentiation and produces malignant osteoid.
- It is the most common histological form of primary bone cancer and it is most prevalent in teenagers and young adults.
- A complete radical, surgical, en bloc resection of the cancer is the treatment of choice in osteosarcoma. Although about 90% of patients are able to have limb-salvage surgery, complications, particularly infection, prosthetic loosening and non-union, or local tumor recurrence may cause the need for further surgery or amputation.
- Standard therapy is a combination of limb-salvage orthopedic surgery when possible (or amputation in some cases) and chemotherapy.
- Ewing sarcoma (ES) is a highly aggressive bone tumor with peak incidence in the adolescent population. It has a high propensity to metastasize, which is associated with dismal survival rates of approximately 25% (Satterfield, L. et al, Int. J. Cancer, 141: 2062-2075; 2017; Beverly A. Teicher et al, Ann Saudi Med., 31(2): 174-182; 2011).
- Members of the Ewing sarcoma family of tumors (ESFT) contain tumor-associated translocations that give rise to oncogenic transcription factors, most commonly EWS/FLl1. EWS/FLl1 plays a dominant role in tumor progression by modulating the expression of hundreds of target genes. Here, the impact of EWS/FLl1 inhibition, by RNAi-mediated knockdown, on cellular signaling was investigated using mass spectrometry-based phosphoproteomics to quantify global changes in phosphorylation. This unbiased approach identified hundreds of unique phosphopeptides enriched in processes such as regulation of cell cycle and cytoskeleton organization. In particular, phosphotyrosine profiling revealed a large upregulation of STAT3 phosphorylation upon EWS/FLl1 knockdown. However, single-cell analysis demonstrated that this was not a cell-autonomous effect of EWS/FLl1 deficiency, but rather a signaling effect occurring in cells in which knockdown does not occur. Conditioned media from knockdown cells were sufficient to induce STAT3 phosphorylation in control cells, verifying the presence of a soluble factor that can activate STAT3. Cytokine analysis and ligand/receptor inhibition experiments determined that this activation occurred, in part, through an IL6-dependent mechanism. Taken together, the data support a model in which EWS/FLl1 deficiency results in the secretion of soluble factors, such as IL6, which activate STAT signaling in bystander cells that maintain EWS/FLl1 expression. Furthermore, these soluble factors were shown to protect against apoptosis (Jennifer L. Anderson et al, Mol Cancer Res; 12(12); 2014; Andrej Lissat et al, BMC Cancer, 15: 552; 2015).
- Rhabdomyosarcoma (RMS) is an aggressive and highly malignant form of cancer that develops from skeletal (striated) muscle cells that have failed to fully differentiate. It is generally considered to be a disease of childhood, as the vast majority of cases occur in those below the age of 18.
- Despite being a relatively rare cancer, it accounts for approximately 40% of all recorded soft-tissue sarcomas. RMS can occur in any site on the body, but is primarily found in the head, neck, orbit, genitourinary tract, genitals, and extremities.
- Treatment of rhabdomyosarcoma is a multidisciplinary practice involving the use of surgery, chemotherapy, radiation, and possibly immunotherapy. Surgery is generally the first step in a combined therapeutic approach. Resectability varies depending on tumor site, and RMS often presents in sites that don’t allow for full surgical resection without significant morbidity and loss of function. Less than 20% of RMS tumors are fully resected with negative margins. Fortunately, rhabdomyosarcomas are generally chemosensitive, with approximately 80% of cases responding to chemotherapy.
- Multi-agent chemotherapy is indicated for all patients with rhabdomyosarcoma. Before the use of adjuvant and neoadjuvant therapy involving chemotherapeutic agents, treatment solely by surgical means had a survival rate of <20%. Modern survival rates with adjuvant therapy are approximately 60-70%.
- Metastasis kills patients with solid tumors. Nowhere is this more evident than in osteosarcoma. The deadly bone cancer osteosarcoma (OS) kills primarily through metastatic spread to lung. The mechanisms driving this lung tropism remain unknown. Whether patients present with grossly metastatic disease at diagnosis or metastases arise many years after completing therapy, patients with localized disease enjoy a relatively favorable 70% 5-year overall survival rate, while those with lung metastasis suffer an abysmal 15% 2-year survival (Allison D. C. et al; Sarcoma 2012, 704872; 2012).
- Despite myriad attempts to augment therapy or to find novel treatments for metastatic disease, no treatment has significantly improved outcomes in over 40 years. Clearly, novel approaches will be needed in order to make inroads in the treatment of metastatic osteosarcoma (Luetke A. et al.; Cancer Treat. Rev. 40, 523-32; 2014). Large consortia of researchers in the field have suggested that further advances in treatment of osteosarcoma will not likely come without an improved understanding of the biology of metastasis and with the development of drugs targeting those pathways (Khanna C. et al, Clin Cancer Res; 20(16); 1-10; 2014).
- Some prior arts refer to the identification of the risk factors associated with the outcome in children with metastatic rhabdomyosarcoma (Oberlin O. et al; Journal of Clinical Oncology, 2008 May 10; 26(14): 2384-2389) and to the outcomes in children with rhabdomyosarcoma (RMS) and lung-only metastatic disease (J. Pediatr. Surg., 2005 Jan.; 40(1):256-62).
- A therapy which prevents the emergence of lung metastasis in children and adolescents with osteosarcoma would save the lives of more than 70% of those who currently die from their disease.
- Interleukin-8 (IL-8; CXCL8) is considered a major mediator of PMN (Polymorphonuclear Neutrophils) recruitment and is involved in several pathologies including psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease and reperfusion injury in transplanted organ (Griffin et al, Arch Dermatol 1988, 124: 216; Fincham et al, J Immunol 1988, 140: 4294; Takematsu et al, Arch Dermatol 1993, 129: 74; Liu et al, 1997, 100:1256; Jeffery, Thorax 1998, 53: 129; Pesci et al, Eur Respir J. 1998, 12: 380; Lafer et al, Br J Pharmacol. 1991, 103: 1153; Romson et al, Circulation 1993, 67: 1016; Welbourn et al, Br J Surg. 1991, 78: 651; Sekido et al, Nature 1993, 365, 654). The biological activity of IL-8 is mediated by the interaction with two receptors, CXCR1 and CXCR2, belonging to the 7 TM-GPCR family, that are expressed on the surface of human PMNs. While CXCR1 is selective, binding with high affinity only two chemokines, CXCL6 and IL-8, and showing a much higher affinity for IL-8 (Wolf et al, Eur J Immunol 1998, 28: 164), human CXCR2 is a more promiscuous receptor, binding a number of different cytokines and chemokines. Therefore, CXCR2 mediates the activity of a number of different biological molecules. Interleukin-6 (IL-6) is a pleiotropic cytokine with multiple functions in immune regulation, inflammation, and oncogenesis. Binding of IL-6 to the IL-6 receptor (IL-6R) induces homodimerization and recruitment of glycoprotein 130 (gp130), which leads to activation of downstream signaling.
- Gp130 is part of the receptor signaling complexes for at least 8 cytokines (IL-6, IL-11, IL-27, LIF, CNTF, OSM, CT-1, and CLC). Ligand binding induces the association of gp130 with a cytokine-specific receptor-a chain, followed by the activation of downstream signaling cascades including JAK/STAT, RAS/RAF/MAPK, and Pl3K/AKT pathways. It has been shown that phosphorylation of gp130 at Ser782 downregulates cell surface expression of gp130. As a ubiquitously expressed receptor, gp130 is involved in a wide range of important biologic processes including inflammation, autoimmunity, cancer, stemcell maintenance, and embryonic development (Mol Cancer Ther; 12(6); 937-49; 2013).
- The present inventors have surprisingly found that inhibition of IL-8 is able to reduce or prevent the occurrence of lung metastasis associated with osteosarcoma, Ewing sarcoma or rhabdomyosarcoma. In particular, the combination of an IL-8 inhibitor with an IL-6 inhibitor is resulted more effective.
- The present inventors have also surprisingly found that an IL-8 inhibitor is useful in the prevention and/or treatment of the primary tumor osteosarcoma, Ewing sarcoma or rhabdomyosarcoma. Preferably, when IL-8 inhibitor is combined with a chemotherapeutic agent.
- Accordingly, a first object of the present invention is an IL-8 inhibitor, preferably an antibody or a small molecular weight molecule, preferably a CXCR1 inhibitor, more preferably a dual CXCR1 /CXCR2 inhibitor, for use in the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
- The second object of the present invention is the use of said IL-8 inhibitor as defined above, for the preparation of a medicament for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
- The third object of the present invention is a method for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof comprising the step of administering to a subject in need thereof a therapeutically effective amount of said IL-8 inhibitor.
- The fourth object of the invention is a pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof comprising an IL-8 inhibitor according to the invention and pharmaceutically acceptable excipients and/or diluents.
- According to one preferred embodiment, said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably lung metastasis, further comprises at least one IL-6 inhibitor and/or at least one gp130 inhibitor.
- According to another preferred embodiment, said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably the primary tumor, further comprises at least one chemotherapeutic agent.
- The fifth and sixth object of the present invention are a product or a kit for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, comprising an IL-8 inhibitor as defined above and one or more pharmaceutically active compounds for simultaneous, separate or sequential use.
-
FIG. 1 shows IL6 and IL8 expression correlate with metastatic efficiency and metastatic behaviors in xenograft models of metastasis.CB17-SCID mice inoculated with 1 ×106 OS cells were euthanized 49 days after innoculation. a) Gross appearance of lung blocks taken from those mice suggests markedly greater efficiency of colonization by OS-17 relative to the other cell lines. b) H&E stains from sections of paraffin-embedded left lobes were counted to quantify the number of metastases per section. c) Quantification reveals significantly higher numbers of metastases in the OS-17 sections relative to OHS. d) Determination of IL-6 and ll-8 concentrations in 72 hour supernatants from cultures of each cell line reveals significant expression of both cytokines in the metastatic OS-17 cells relative to either non-metastatic cell line. e)-f) Evaluation of capacity to respond to IL-6 and IL-8 signals using transwell migration assay. -
FIG. 2 shows effect of DF2156A alone or in combination with sc144 to reduce chemotactic responses to serum in OS-17 cells. OS cells were cultured on a transwell chamber membrane, then subjected transferred to a chamber containing RPMI with 2.5% FBS (pos ctl) or RPMI alone (neg ctl). Other wells containing 2.5% FBS in the bottom chamber were treated with 1 uM sc144, 10 nM DF2156A, or both. After 24 hours, top chambers were scraped clean, membranes stained and cells counted. -
FIG. 3 shows effects of IL-6 and IL-8 pathway inhibition on metastatic lung colonization. Mice innoculated with 1 ×106 OS-17-luc cells were treated with pharmacologic inhibitors of IL-6 (sc144), IL-8 (DF2156A), or both. A) Bioluminescent imaging completed at 28 days post-inoculation. B) Survival analysis of the mice shown in A). -
FIG. 4 shows PD analysis in lung tissue of mice treated with DF2156A and sc144. Mice treated with injections of either DF2156A or sc144 daily were euthanized 24 hours subsequent to their 14th dose of drug. Lungs harvested from those mice were processed using standard FFPE, then sectioned and stained with IHC for either pFAK (downstream of IL-8) or pSTAT3 (downstream of IL-6). Receptor blockade reduced the amount of activation seen and the number of infiltrating cells, even at trough concentrations. -
FIG. 5 shows effect of the combination DF2156A with sc144 in the prevention of lung metastasis in multiple models of OS. Subsequent to inoculation of OS cells, mice received either vehicle treatment or treatment with both sc144 and DF2156A for a period of 42 days. At the time that one mouse in either group met endpoint criteria, all mice within that study were euthanized and lungs harvested, metastatic lesions counted. - As it will be disclosed in details in the Experimental Section, the present inventors have found that molecules acting as inhibitors of IL-8 activity have therapeutic efficacy in animal models of sarcoma. Furthermore, the present inventors have also found that IL-8 inhibition is able to counteract the onset of lung metastasis. In particular, the combined IL-8 and IL-6 inhibition prevents metastasis.
- Accordingly, a first object of the present invention is an IL-8 inhibitor for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- According to a preferred embodiment, said IL-8 inhibitor is for use in the prevention and/or treatment of lung metastasis associated to osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- The term “lL-8-inhibitor” according to the present application refers to any compound able to inhibit, partially or totally, the biological activity of IL-8. Such a compound can act by decreasing the expression or activity of IL-8 or by inhibiting the triggering of the intracellular signaling activated by the IL-8 receptors. It is preferred that said IL-8 inhibitor is able to inhibit at least 50%, preferably at least 60%, of the chemotaxis induced by IL-8 in PMNs at a concentration equal or below 500 nM, preferably below 100 nM.
- According to a preferred embodiment, the IL-8 inhibitor of all the objects of the present invention inhibits the activity of IL-8 mediated by CXCR1 receptor or mediated by both CXCR1 and CXCR2 receptors.
- Preferably, according to this embodiment, said IL-8 inhibitor is either an allosteric inhibitor or an orthosteric antagonist of CXCR1 receptor or of both CXCR1 and CXCR2 receptors.
- Preferably, said IL-8 inhibitor is selective for CXCR1 receptor or is equally potent towards CXCR1 and CXCR2 receptors.
- By “selective for CXCR1” according to the present invention it is meant a compound that shows an IC50 value at least 2, preferably 3, logs higher toward CXCR1 than towards CXCR2. (Bertini R. et al., Proc. Nat. Acad. Sci. USA (2004), 101 (32), pp. 11791-11796).
- By “equally potent towards CXCR1 and CXCR2” it is meant a compound that shows an IC50 value in the
range 10 picomolar (10-11 M) - 1 micromolar (10-6 M) towards CXCR1 and CXCR2. (Bertini R. et al., Br. J. Pharm. (2012), 165, pp. 436-454). - More preferably, the IL-8 inhibitor according to the invention has an IC50 value towards CXCR1 receptor in the low nanomolar range, preferably in the range 0.02-5 nanomolar.
- According to a preferred embodiment, also in combination with the preceding embodiment, said IL-8 inhibitor is selected from small molecular weight molecules and antibodies, more preferably it is a small molecular weight molecule.
- IL-8 inhibitors according to the above definition, able to inhibit the activity of IL-8 mediated by CXCR1 receptor or mediated by both CXCR1 and CXCR2 receptors, are known in the art.
- Preferred IL-8 inhibitors according to the invention are selected from 1,3-thiazol-2-ylaminophenylpropionic acid derivatives, 2-phenyl-propionic acid derivatives and their pharmaceutically acceptable salts.
- Among the above compounds, said 1,3-thiazol-2-ylaminophenylpropionic acid derivative is preferably a compound of formula (l):
- or a pharmaceutically acceptable salt thereof, wherein
- -R1 is hydrogen or CH3;
- -R2 is hydrogen or linear C1-C4 alkyl, preferably it is hydrogen;
- -Y is a heteroatom selected from S, O and N; preferably it is S;
- -Z is selected from halogen, linear or branched C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, hydroxyl, carboxyl, C1-C4 acyloxy, phenoxy, cyano, nitro, amino, C1-C4 acylamino, halo C1-C3 alkyl, halo C1-C3 alkoxy, benzoyl, linear or branched C1-C8 alkanesulfonate, linear or branched C1-C8 alkanesulfonamide, linear or branched C1-C8 alkylsulfonylmethyl; preferably it is trifluoromethyl;
- -X is OH or a residue of formula NHR3; wherein R3 is selected from:
- -hydrogen, hydroxyl, linear or branched C1--C6 alkyl, C3-C6 cycloalkyl, C2--C6 alkenyl, C1-C5 alkoxy,
- or C1-C6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue
- a residue of formula SO2R4 wherein R4 is C1-C2 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl.
- -hydrogen, hydroxyl, linear or branched C1--C6 alkyl, C3-C6 cycloalkyl, C2--C6 alkenyl, C1-C5 alkoxy,
- Preferably, in the above compounds X is OH.
- Among the above compounds, particularly preferred are compounds of said formula (l) or pharmaceutically acceptable salts thereof, wherein:
- R1 is CH3;
- R2 is hydrogen or linear C1-G4 alkyl, preferably it is hydrogen;
- Y is a heteroatom selected from S, O and N; preferably it is S;
- Z is selected from halogen, linear or branched C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, hydroxyl, carboxyl, C1-C4 acyloxy, phenoxy, cyano, nitro, amino, C1-C4 acylamino, halo C1-C3 alkyl, halo C1-C3 alkoxy, benzoyl, linear or branched C1-C8 alkanesulfonate, linear or branched C1-C8 alkanesulfonamides, linear or branched C1-C8 alkylsulfonylmethyl; preferably it is trifluoromethyl;
- X is OH or a residue of formula NHR3; wherein R3 is selected from:
- -hydrogen, hydroxyl, linear or branched C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C1-C5 alkoxy,
- or C1-C6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue
- a residue of formula SO2R4 wherein R4 is C1-C2 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl.
- -hydrogen, hydroxyl, linear or branched C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C1-C5 alkoxy,
- Preferably, in these compounds X is OH.
- Among the above compounds, particularly preferred are also compounds of said formula (l) or pharmaceutically acceptable salts thereof, wherein
- R1 is hydrogen;
- R2 is hydrogen or linear C1-C4 alkyl, preferably it is hydrogen;
- Y is a heteroatom selected from S, O and N; preferably it is S;
- Z is selected from halogen, linear or branched C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, hydroxyl, carboxyl, C1-C4 acyloxy, phenoxy, cyano, nitro, amino, C1-C4 acylamino, halo C1-C3 alkyl, halo C1-C3 alkoxy, benzoyl, linear or branched C1-C8 alkanesulfonate, linear or branched C1-C8 alkanesulfonamides, linear or branched C1-C8 alkylsulfonylmethyl; preferably it is selected from trifluoromethyl;
- X is OH or a residue of formula NHR3; wherein R3 is selected from
- -hydrogen, hydroxyl, linear or branched C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C1-C5 alkoxy,
- or C1-C6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue;
- a residue of formula SO2R4 wherein R4 is C1-C2 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl. More preferably X is NH2.
- -hydrogen, hydroxyl, linear or branched C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C1-C5 alkoxy,
- Preferably, in the above compounds X is OH.
- Among the above compounds, particularly preferred are also compounds of said formula (l) or pharmaceutically acceptable salts thereof, wherein:
- R1 is hydrogen or CH3 ;
- R2 is hydrogen or linear C1-C4 alkyl, preferably it is hydrogen;
- Y is a heteroatom selected from S, O and N; preferably it is S;
- Z is selected from linear or branched C1-C4 alkyl, linear or branched C1-C4 alkoxy, halo C1-C3 alkyl and halo C1-C3 alkoxy; preferably it is selected from methyl, methoxy, trifluoromethoxy, trifluoromethyl, more preferably it is trifluoromethyl;
- X is OH.
- Among the above compounds, particularly preferred are also compounds of said formula (l) or pharmaceutically acceptable salts thereof, wherein :
- R1 is CH3 ;
- R2 is hydrogen or linear C1-C4 alkyl, preferably it is hydrogen.
- Y is a heteroatom selected from S, O and N; preferably it is S.
- Z is selected from linear or branched C1-C4 alkyl, linear or branched C1-C4 alkoxy, halo C1-C3 alkyl and halo C1-C3 alkoxy; preferably it is selected from methyl, methoxy, trifluoromethoxy, trifluoromethyl, more preferably it is trifluoromethyl. Among the above compounds, particularly preferred are also compounds of said formula (l) or pharmaceutically acceptable salts thereof, wherein R1 is hydrogen;
- X is OH;
- R2 is hydrogen or linear C1-C4 alkyl, preferably it is hydrogen;
- Y is a heteroatom selected from S, O and N; preferably it is S;
- Z is selected from linear or branched C1-C4 alkyl, linear or branched C1-C4 alkoxy, halo C1-C3 alkyl and halo C1-C3 alkoxy; preferably it is trifluoromethyl.
- Preferably, in all of the above compounds of formula (I) wherein R1 is hydrogen, the chiral carbon atom of the phenylpropionic group is in the S configuration.
- Particularly preferred are compounds of formula (I) according to the invention selected from 2-methyl-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino} phenyl)propanoic acid (herein indicated also as DF2726Y) and pharmaceutically acceptable salts thereof, preferably its sodium salt (herein indicated also as DF2726A) and 2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and pharmaceutically acceptable salts thereof, preferably (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid (also known as DF2755Y) and its sodium salt, also known as DF2755A.
- Compounds of formula (l) are disclosed in WO2010/031835, which also discloses their method of synthesis, their activity as IL-8 inhibitors as well as their use in the treatment of IL-8 dependent pathologies such as transient cerebral ischemia, bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion.
- Among the above IL-8 inhibitors, said 2-phenyl-propionic acid derivative is preferably a compound of formula (II):
- or a pharmaceutically acceptable salt thereof, wherein
- R4 is linear or branched C1-C6 alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy; preferably it is selected from benzoyl, isobutyl and trifluoromethanesulfonyloxy. Also, according to a preferred embodiment R4 is in position 3 or 4 on the phenyl ring, more preferably it is 3-benzoyl, 4-isobutyl or 4- trifluoromethanesulfonyloxy.
- R5 is H or linear or branched C1-C3 alkyl, preferably it is H.
- R6 is linear or branched C1-C6 alkyl or trifluoromethyl; preferably, it is a linear or branched C1-C6 alkyl, more preferably it is CH3.
- Among the above compounds, preferred are compounds of formula (II) or a pharmaceutically acceptable salts thereof, wherein:
- R4 is C1-C6 alkyl or benzoyl; preferably it is in positions 3 and 4, more preferably, it is 3-benzoyl or 4-isobutyl.
- R5 is H or linear or branched C1-C3 alkyl, preferably it is H,
- R6 is linear or branched C1-C6 alkyl or trifluormethyl; preferably it is a linear or branched C1-C6 alkyl, more preferably it is CH3.
- Among the above compounds, preferred are compounds of formula (II) or a pharmaceutically acceptable salts thereof, wherein:
- R4 is trifluoromethanesulfonyloxy, preferably 4-trifluoromethanesulfonyloxy,
- R5 is H or linear or branched C1-C3 alkyl, preferably it is H,
- R6 is linear or branched C1-C6 alkyl or trifluormethyl; preferably it is a linear or branched C1-C16 alkyl, more preferably it is CH3.
- Among the above compounds, also preferred are compounds of formula (lll):
- or a pharmaceutically acceptable salts thereof, wherein
- R′ is hydrogen;
- R is a residue of formula SO2Ra wherein Ra is linear or branched C1-C4 alkyl or halo C1-C3 alkyl, preferably it is CH3.
- Preferably, in the above compound of formula (II) or (III), the chiral carbon atom of the phenylpropionic group is in the R configuration.
- Particularly preferred compounds of formula (II) according to the invention are selected from R-(-)-2-(4-isobutylphenyl)propionyl methansulfonamide (also known as Reparixin) and pharmaceutically acceptable salts thereof. Preferably, said compound is the lysine in situ salt of R(-)-2-(4-isobutylphenyl)propionyl methansulfonamide (herein indicated also as DF1681B).
- Further particularly preferred compounds of formula (II) or (III) according to the invention are 2-(4-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide and pharmaceutically salts thereof, preferably its sodium salt preferably R(-)-2-(4-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide (also known as DF2156Y) and its sodium salt (also known as Ladarixin or DF2156A).
- IL-8 inhibitors of formula (II) and (III) are disclosed in WO0024710 and WO2005/090295, that also disclose their method of synthesis, their activity as IL-8 inhibitors as well as their use as inhibitors of neutrophils chemotaxis and degranulation induced by IL-8 and in the treatment of IL-8 dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary diseases (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion.
- The second object of the present invention is the use of an IL-8 inhibitor for the preparation of a medicament for the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- According to a preferred embodiment of the present invention, said medicament is for the treatment and/or prevention of lung metastasis associated to bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- The third object of the present invention is a method for the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma, comprising the step of administering to the subject in need thereof, a therapeutically effective amount of an IL-8 inhibitor, as defined above.
- According to a preferred embodiment of the present invention, said method is for the treatment and/or prevention of lung metastasis associated to bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- As used herein, a “therapeutically effective amount” refers to an amount sufficient to achieve treatment or prevention of the disease. Determination of the effective amounts is well within the capability of those skilled in the art based upon the achievement of a desired effect. An effective amount will depend on factors including, but not limited to, the weight of a subject and/or the degree of the disease or unwanted condition from which a subject suffers.
- The terms “treatment” and “prevention” as used herein refer to the eradication/amelioration or prevention/delay in onset, respectively, of the disorder being treated or of one or more of the symptoms associated thereof, notwithstanding the fact that the patient may still be afflicted with the underlying disorder.
- The fourth object of the present invention is a pharmaceutical composition comprising an IL-8 inhibitor as defined above, for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof in association with pharmaceutically acceptable excipients and/or diluents.
- According to one preferred embodiment, said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably lung metastasis, further comprises at least one IL-6 inhibitor and/or at least one gp130 inhibitor.
- The term “IL-6 inhibitor” according to the present application refers to any compound able to inhibit, partially or totally, the biological activity of IL-6.
- The term “gp130 inhibitor” according to the present application refers to any compound able to inhibit, partially or totally, the biological activity of gp130. According to another preferred embodiment, said pharmaceutical composition for the prevention and/or treatment of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof, more preferably the primary tumor, further comprises at least one chemotherapeutic agent.
- The fifth object of the present invention is a product or kit comprising: A) an IL-8 inhibitor as defined above for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof or a pharmaceutical composition as defined above, and B) at least one IL-6 inhibitor and/or at least one gp130 inhibitor, A) and B) being two separate formulations for simultaneous, separate or sequential use. Preferably, for use in the treatment and/or prevention of lung metastasis associated to osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- According to one preferred embodiment, said gp130 inhibitor is selected from the group comprising 2-(7-Fluoropyrrolo[1,2-a]quinoxalin-4-yl) 2-pyrazinecarboxylic acid hydrazide (SC144), Raloxifene and (4R)-3-((2 S,3 S)-3-hydroxy-2-methyl-4-methylenenonanoyl)-4-isopropyldihydrofuran-2(3H)-one (LMT-28) (Tae-Hwe Heo et al.; Oncotarget, Vol. 7, No. 13, 15460- 15473; 2016).
- According to one preferred embodiment, said IL-6 inhibitor is selected from the group comprising SC144, Vobarilizumab, Siltuximab, Sirukumab, Olokizumab, Clazakizumab, MAb 1339, Tocilizumab and Sarilumab (Tae-Hwe Heo et al.; Oncotarget, Vol. 7, No. 13, 15460- 15473; 2016).
- Preferably, said IL-6 inhibitor is SC144.
- The sixth object of the present invention is a product or kit comprising: A′) an IL-8 inhibitor as defined above for use in the treatment and/or prevention of bone and soft tissue sarcomas, preferably osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof or a pharmaceutical composition as defined above, and B′) at least one chemotherapeutic agent, A′) and B′) being two separate formulations for simultaneous, separate or sequential use. Preferably, for use in the treatment and/or prevention of the primary tumor osteosarcoma, Ewing sarcoma or rhabdomyosarcoma.
- Preferably, said chemotherapeutic agent is selected from the group comprising doxorubicin, cisplatin, methotrexate, ifosfamide, epirubicin, etoposide, cyclophosphamide, vincristine and actinomycin D.
- For the purpose of the present invention, the inhibitors of IL-8 according to the present invention are formulated in pharmaceutical compositions suitable for use by oral formulation, such as tablets, capsules, syrups, preferably in the form of controlled release formulations, or by parenteral administration, preferably in the form of sterile solutions suitable for intravenous or intramuscular administration. The pharmaceutical compositions can be prepared according to conventional methods, for example as disclosed in Remington, “The Science and Practice of Pharmacy”, 21st ed. (Lippincott Williams and Wilkins).
- The average daily dose depends on several factors such as the severity of the disease, the condition, age, sex and weight of the patient. The dose will vary generally from 1 to 1500 mg of compounds of formula (l) per day optionally divided in multiple administrations.
- The invention will be further illustrated in greater details in the following experimental section.
- Cell lines and primary cell cultures. OS-17 was derived from the OS-17 xenograft and obtained from the Istituti Ortopedici Rizzoli, Bologna, Italy. OS-25 and OHS were a gift from Dr. Fodstad’s lab at the Radium Hospital in Oslo. All were maintained in RPMI (Corning #10-040-CV) supplemented with 10% FBS (Atlanta Biologicals #S11150H). 143B and K7M2 cells were obtained from ATCC (ATCC #CRL¬8303 and #CRL2836) and grown in DMEM (Corning #10-013-CV) supplemented with 10% FBS. OSCA-8 and OSCA-16 were provided by Jamie Modiano and the University of Minnesota and grown in RPMI with 10% FBS. Lung smooth muscle cells (ATCC #PCS-130-10) were grown in vascular cell basal medium (ATCC #PCS-100-030) supplemented with the vascular smooth muscle cell growth kit (ATCC #PCS-100-042). HUVEC cells (Lonza CC-2517) were grown in endothelial basal medium (Lonza #CC-5036) supplemented with the EGM-plus single quote (Lonza #CC-4542). Human lung fibroblasts (ATCC #PCS-201-013) were grown in EMEM (ATCC #30-2003) supplemented with 10% FBS. HBEC3-KT cells (ATCC #CRL-4051) were grown in airway epithelial cell basal medium (ATCC #PCS-300-030) supplemented with the bronchial epithelial cell growth kit (ATCC #PCS-300-040). Macrophages were derived from monocytes isolated from whole blood (obtained through an institutional IRB-approved protocol for the procurement of fresh human blood) using a CD14 magnetic bead selection system (Miltenyi #130-050-201) followed by 72 hours of culture in XVIVO serum-free medium (Lonza #04-380Q) supplemented daily with 20 ng/ml of recombinant human M-CSF (BioLegend #574802). For co-culture experiments, cultures within each group (co-culture and related monocultures) were performed using a 1:1 mixture of the two corresponding growth media to control for differences in media components.
- IL-6 and IL-8 ELISA. Cell-free supernatants from 72-hour cultures of each cell line performed in 24-well plates were evaluated for IL-6 and IL-8 concentrations using R&D DuoSet ELISA Development Kits (#DY206 and #DY208), used according to manufacturer recommendations.
- Scratch (“wound healing”) assays. Monolayer cultures of OS-17 or OHS cell lines were disrupted using an Essen Incucyte WoundMaker (Essen Cell Migration Kit #4493). Individual wells were then serially imaged using an Essen Incucyte Zoom. Analysis was performed and wound width quantified using Essen’s Integrated Cell Migration Analysis Module (Essen # 9600-0012).
- Transwell migration and invasion assays. 1 × 104 OS cells were plated into transwell inserts (either Falcon #353097 for migration or Corning #354483 for Matrigel invasion assays) containing appropriate chemotactic factors. After 24 hours of incubation, transwells were drained and upper chambers/membrane upper surfaces scraped using a polyester swab. Membranes were stained using a Dif-Quik Stain Set (Siemens #B4132-1A) and dried, then imaged on an inverted microscope. Cells were quantified using Adobe Photoshop counting tools. For experiments involving IL-6 and IL-8 chemotaxis, media contained 1% FBS in both chambers, with recombinant protein added to the bottom chamber to make 50 ng/ml IL6 (BioLegend #570804) or 100 ng/ml IL-8 (BioLegend #574204). For experiments using serum as a chemoattractant, top chambers contained RPMI only, while bottom chambers contained 1% or 2.5% serum. Where noted, 20 ug/ml of neutralizing antibodies to either IL6 (Abcam #AB6672), IL-8 (Abcam #AB18672), or both were added to both upper and lower chambers. In experiments testing the ability of small molecules to block serum-induced migration/invasion, 1 µM sc144 (Sigma #SML0763) and/or 100 nM DF2156A (Dompe Pharmaceuticals, Milan, Italy) was added to the media.
- OS cell proliferation. Cells plated at 20% confluence were cultured in growth medium as above containing inhibitors as noted in each figure. Proliferation was serially quantified using an Essen Biosciences Incucyte Zoom over the time period noted in each figure.
- Colony formation. 1 × 104 OS cells were plated in 1.5 ml of 0.5% soft agar (Lonza SeaPlaque GTG Agarose, #50111 in Gibco powdered RPMI #430-1800) over a 1.5 ml bed of 1% soft agar in 6 well plates, then covered with 500 ml RPMI. Where noted, drug was added to the RPMI layer sufficient to generate the stated concentration when diffused throughout both media and agar.
- Xenograft survival studies. 6-8 week old CB17-SCID (Envigo C.B-17/lcrHsd-Prkdcscid) mice inoculated via tail vein with 1 × 106 OS-17 cells (day 0) received daily injections of sc144 (10 mg/kg SC once daily, Sigma #SML0763), DF2156A (30 mg/kg IP once daily), or both beginning 24 hours after inoculation. sc144 was prepared by dissolving with warming in DMSO to make a 40 mg/kg solution, which was immediately diluted to 2 mg/kg using 40% propylene glycol/1% Tween-20 in water. An average 20 g mouse received 100 ul per dose. Doses of sc144 were prepared fresh each day. DF2156A was prepared by dissolving in PBS to create a 6 mg/ml solution for similar 100 ul doses in a 20 g mouse. Treatments continued for 42 days, then stopped. Mice were monitored with twice weekly weights and enhanced body condition scoring (eBCS (28)). Mice demonstrating >10% weight loss or eBCS <8 were euthanized and tissues harvested, lungs insufflated, fixed in 10% neutral buffered formalin, then embedded and processed as above. Mice not demonstrating metastatic disease burden (presumably dying from other causes) are censored in the survival analysis. This includes 2 mice receiving combined therapy, one receiving sc144, and one control mouse.
- Timepoint treatment studies. 6-8 week old CB17-SCID mice were inoculated with 1 × 106 143B, OSCA-8, OSCA-16, or K7M2 cells (for K7M2 cells, immunocompetent Balb/c mice were used). 24 hours after inoculation, mice began treatment with daily sc144 and/or DF2156A, which continued for 42 days as above. Mice were then observed as above until one mouse from any given cell line group reached endpoint. If lungs taken from this sentinel mouse showed signs of metastatic disease, all mice from that group were euthanized, lungs harvested, insufflated, fixed, embedded, and stained. A central section of the left lobe stained with H&E was reviewed using microscopy to count metastatic lesions by an experienced, blinded reviewer.
- Statistical Analysis. Data were graphed and analyzed using Graphpad Prism 7. The specific statistical tests used and comparisons made are identified in the caption for each figure. Where necessary, adjustment for multiple comparisons was performed using the Benjamini-Hochberg method to control for a false discovery rate of 0.05.
- The present inventors tested a panel of osteosarcoma cell lines for their ability to colonize mouse lung. The present inventors found that OS-17 cells, when introduced into circulation via tail vein, develop metastatic loci with very high efficiency, while OHS cell lines demonstrate much lower metastatic efficiency (
FIG. 1 ). This effect remained consistent across multiple passages of cells and multiple assays. The present inventors tested these cell lines for production of IL-6 and IL-8 by subjecting cell-free supernatants to ELISA (FIG. 1 d ), which revealed a strong correlation between tumor cell production of both of these cytokines and the cell line’s capacity to colonize murine lung. - To demonstrate whether these highly- and poorly-metastatic cell lines maintain features that respond to these cytokines, we performed both scratch assays (wound-healing assays) and transwell migration assays to assess response. Standardized wounds created in both OS-17 and OHS cell monolayers closed more effectively when cultured in media supplemented with IL-6 and/or IL-8, demonstrating that either cytokine can stimulate chemokinesis (increased cell motility) in either cell line, irrespective of any basal production of that cytokine. These cells exhibit similar results in assays testing directional migration. Both OS-17 and OHS cells grown in the top chamber of a transwell system exhibit strong directional migration in response to chemotactic gradients of either IL-6 or IL-8.
- To determine the importance of these cytokines to OS cell migration within a much broader milieu of possible chemotactic factors, the present inventors examined the effect that IL-6 and/or IL-8 blockade might have when using serum as a chemoattractant. Both cell lines demonstrated very strong both transwell migration and invasion through a matrigel barrier in response to a chemotactic gradient of serum (
FIGS. 1 e-f ). Some decrease in the chemotactic response was evident when IL-6 or IL-8 blocking antibodies were added to the culture medium, though a much more profound effect was seen when the antibodies were combined. A more profound effect was seen in similar experiments using small molecule inhibitors of the receptors for IL-6 and IL-8 (sc144, which stimulates degradation of gp130 through a novel mechanism and DF2156A, an allosteric inhibitor of CXCR1 and CXCR2). With inhibition at the receptor level, blockade of either pathway suffices to prevent directional migration and invasion (FIG. 2 ), suggesting that some level of activation of these pathways, likely by non-IL-6 and non-IL-8 cytokines, is needed for OS cells to produce these behaviors. Both inhibitors significantly decreased the amount of migration of OS cells. - To evaluate the functional importance of IL-6 and IL-8 pathways to OS lung metastasis, the present inventors used the xenograft models. Balb-SCID mice inoculated via tail vein with 1×106 luciferase-labeled OS-17 cells received treatment with sc144 (the gp130 inhibitor), DF2156A (the CXCR½ inhibitor), or both. Mice continued to receive treatment for 42 days, after which treatment stopped. Intravital imaging for in vivo assessment of tumor burden was performed at 14 and 24 days using standard bioluminescent techniques. Bioluminescent imaging suggested markedly decreased tumor burden in the lungs of mice receiving combined therapy relative to those receiving no treatment or single-agent therapy (
FIG. 3 A ). Importantly, imaging did not show migration of the tumor cells into other organs, but an overall loss of bioluminescence, suggesting decreased overall survival of circulating tumor cells. Two mice from each single-agent treatment group were euthanized 24 hours after the 14th dose of drug to perform pharmacodynamics (PD) assessment of target inhibition. Lungs from those mice stained with IHC for either pFAK (DF2156A) or pSTAT3 (gp130) showed sustained target inhibition (i.e. sustained drug activity) at dosing trough (FIG. 4 ). - Following treatment, mice were then observed until demonstrating signs of clinical deterioration, either weight loss >10% or enhanced body condition score (eBCS) <8, our defined endpoints. At endpoint, mice were euthanized using approved methods and lungs were harvested, insufflated, fixed, embedded, sectioned, and stained. Survival analysis (
FIG. 3 B ) showed that nearly all mice receiving either no drug or single agent therapy developed lethal lung metastasis by 60 days. In particular, the mice receiving no drug developed lethal lung metastasis earlier than mice receiving single agent. Whereas most mice receiving combined therapy (gp130 inhibitor + CXCR½ inhibitor) remained healthy at >100 days. Mice which did not demonstrate overt lung metastasis on lung sections were censored from the survival analysis (n=2). - To ensure that the results obtained in these studies were broadly applicable and not unique to immunodeficient xenografts or to OS-17 cells, the present inventors repeated the treatment-related experiments using a number of different models. These included a syngeneic, immunocompetent model using a cell line derived from a spontaneously-arising OS in a Balb/c mouse (K7M2), xenograft models of canine OS (OSCA-8 and OSCA-16), and additional xenograft models of human OS (143B). Mice inoculated with tumor cells were treated with either no drug or combined sc144 and DF2156A for 42 days. At the time that at least one mouse from any group (any cell line) reached endpoint with confirmed lung metastasis, all mice from that group were euthanized, lungs harvested, and metastatic lesions quantified. The ability of dual gp130-CXCR½ inhibition to prevent the development of metastatic lung lesions remained consistent across models (
FIG. 5 ).
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/135,460 US20230248704A1 (en) | 2017-10-24 | 2023-04-17 | Il-8 inhibitors for use in the treatment of some sarcomas |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17198072.5 | 2017-10-24 | ||
EP17198072.5A EP3476390A1 (en) | 2017-10-24 | 2017-10-24 | Il-8 inhibitors for use in the treatment of sarcomas |
PCT/EP2018/078971 WO2019081470A1 (en) | 2017-10-24 | 2018-10-23 | Il-8 inhibitors for use in the treatment of some sarcomas |
US202016764270A | 2020-05-14 | 2020-05-14 | |
US18/135,460 US20230248704A1 (en) | 2017-10-24 | 2023-04-17 | Il-8 inhibitors for use in the treatment of some sarcomas |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/078971 Division WO2019081470A1 (en) | 2017-10-24 | 2018-10-23 | Il-8 inhibitors for use in the treatment of some sarcomas |
US16/764,270 Division US11660291B2 (en) | 2017-10-24 | 2018-10-23 | IL-8 inhibitors for use in the treatment of some sarcomas |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230248704A1 true US20230248704A1 (en) | 2023-08-10 |
Family
ID=60162145
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/764,270 Active US11660291B2 (en) | 2017-10-24 | 2018-10-23 | IL-8 inhibitors for use in the treatment of some sarcomas |
US18/135,460 Pending US20230248704A1 (en) | 2017-10-24 | 2023-04-17 | Il-8 inhibitors for use in the treatment of some sarcomas |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/764,270 Active US11660291B2 (en) | 2017-10-24 | 2018-10-23 | IL-8 inhibitors for use in the treatment of some sarcomas |
Country Status (11)
Country | Link |
---|---|
US (2) | US11660291B2 (en) |
EP (2) | EP3476390A1 (en) |
JP (2) | JP2021500413A (en) |
KR (2) | KR20200091405A (en) |
AU (1) | AU2018356497B2 (en) |
BR (1) | BR112020007940A2 (en) |
CA (1) | CA3079781A1 (en) |
IL (1) | IL274031B2 (en) |
MA (1) | MA50449A (en) |
SG (1) | SG11202003622TA (en) |
WO (1) | WO2019081470A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017220539A1 (en) | 2017-11-17 | 2019-05-23 | Zf Friedrichshafen Ag | A method of operating a system of an agricultural work vehicle and at least one work implement disposed thereon |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1303249B1 (en) | 1998-10-23 | 2000-11-06 | Dompe Spa | SOME N- (2-ARYL-PROPIONYL) -SULPHONAMIDS AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM. |
US20030096781A1 (en) * | 2001-08-31 | 2003-05-22 | University Of Southern California | IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma |
CN1934077B (en) | 2004-03-23 | 2010-09-29 | 冬姆佩制药股份公司 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
LT2356462T (en) | 2008-11-11 | 2017-03-10 | The Regents Of The University Of Michigan | Anti-cxcr1 compositions and methods |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
MA41044A (en) * | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
US20170165363A1 (en) * | 2015-12-11 | 2017-06-15 | The Johns Hopkins University | Cancer cell migration inhibitors and their use in therapeutic treatments |
CN108463219B (en) | 2016-01-15 | 2021-09-17 | 东佩制药股份公司 | IL-8 inhibitors for the treatment of chemotherapy-induced peripheral neuropathy |
US10660909B2 (en) * | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
-
2017
- 2017-10-24 EP EP17198072.5A patent/EP3476390A1/en not_active Withdrawn
-
2018
- 2018-10-23 JP JP2020543705A patent/JP2021500413A/en active Pending
- 2018-10-23 SG SG11202003622TA patent/SG11202003622TA/en unknown
- 2018-10-23 BR BR112020007940-5A patent/BR112020007940A2/en unknown
- 2018-10-23 US US16/764,270 patent/US11660291B2/en active Active
- 2018-10-23 AU AU2018356497A patent/AU2018356497B2/en active Active
- 2018-10-23 MA MA050449A patent/MA50449A/en unknown
- 2018-10-23 KR KR1020207014674A patent/KR20200091405A/en not_active Application Discontinuation
- 2018-10-23 KR KR1020237037725A patent/KR20230156797A/en not_active Application Discontinuation
- 2018-10-23 EP EP18795414.4A patent/EP3700514A1/en active Pending
- 2018-10-23 WO PCT/EP2018/078971 patent/WO2019081470A1/en unknown
- 2018-10-23 CA CA3079781A patent/CA3079781A1/en active Pending
-
2020
- 2020-04-19 IL IL274031A patent/IL274031B2/en unknown
-
2023
- 2023-04-17 US US18/135,460 patent/US20230248704A1/en active Pending
- 2023-09-01 JP JP2023141971A patent/JP2023164916A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018356497B2 (en) | 2024-02-29 |
US11660291B2 (en) | 2023-05-30 |
RU2020116757A3 (en) | 2021-11-30 |
SG11202003622TA (en) | 2020-05-28 |
CA3079781A1 (en) | 2019-05-02 |
BR112020007940A2 (en) | 2020-10-20 |
IL274031B2 (en) | 2023-06-01 |
US20210361627A1 (en) | 2021-11-25 |
KR20200091405A (en) | 2020-07-30 |
MA50449A (en) | 2020-09-02 |
JP2021500413A (en) | 2021-01-07 |
AU2018356497A1 (en) | 2020-06-11 |
KR20230156797A (en) | 2023-11-14 |
RU2020116757A (en) | 2021-11-30 |
IL274031A (en) | 2020-06-30 |
WO2019081470A1 (en) | 2019-05-02 |
EP3476390A1 (en) | 2019-05-01 |
JP2023164916A (en) | 2023-11-14 |
EP3700514A1 (en) | 2020-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | The natural compound notopterol binds and targets JAK2/3 to ameliorate inflammation and arthritis | |
JP7195283B2 (en) | Tinostamstine for use in the treatment of T-cell prolymphocytic leukemia | |
JP2015212305A (en) | Treatment of jak2-medicated conditions | |
US10434100B2 (en) | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | |
US20230248704A1 (en) | Il-8 inhibitors for use in the treatment of some sarcomas | |
US20060183784A1 (en) | Human growth hormone antagonists | |
US7851443B2 (en) | Combination comprising combretastatin and anticancer agents | |
EP1633317A2 (en) | Synthetic chemokine receptor ligands and methods of use thereof | |
US20240033266A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
US20190328706A1 (en) | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof | |
KR20190052255A (en) | Composition for preventing or treating cancer comprising IDF-11774 and autolysosome formation inhibitor | |
RU2787821C2 (en) | Il-8 inhibitors for use in treatment of some sarcomas | |
CN111343973A (en) | IL-8 inhibitors for the treatment of certain sarcomas | |
KR20150083353A (en) | Pharmaceutical composition for prevention or treatment of bladder tumor via intravesical instillation | |
US20220047573A1 (en) | Methods for treating vascular malformations | |
Niwa et al. | Effect of a dihydropyridine analogue, 2-[benzyl (phenyl) amino] ethyl 1, 4-dihydro-2, 6-dimethyl-5-(5, 5-dimethyl-2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin | |
US11241421B2 (en) | Combination therapies for treating cancer | |
AU2021320511B2 (en) | Composition for treating KCA3.1 channel-mediated diseases comprising phenylalkyl carbamate compound | |
CN111166756B (en) | 20 Use of (S) -ginsenoside-Rg 3 in reversing drug resistance of glioma cells to chemotherapeutic drugs | |
EP4219456A1 (en) | Csf1r kinase inhibitor and use thereof | |
JP2018517788A (en) | Combination therapy using belinostat and pralatrexate to treat lymphoma | |
JPWO2007013696A1 (en) | Antitumor agent comprising 6'-amidino-2'-naphthyl 4-guanidinobenzoate or a salt thereof | |
WO2022236173A1 (en) | Treating liver disease | |
Ribeiro | Bomedemstat tosylate. Lysine-specific demethylase 1 inhibitor, Treatment of essential thrombocythemia, Treatment of polycythemia vera, Treatment of myelofibrosis | |
WO2024023278A1 (en) | Cancer combination therapy including a flt3-inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBERTS, RYAN DAVID;BRANDOLINI, LAURA;REEL/FRAME:063357/0912 Effective date: 20210113 Owner name: DOMPE' FARMACEUTICI S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBERTS, RYAN DAVID;BRANDOLINI, LAURA;REEL/FRAME:063357/0912 Effective date: 20210113 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |